BRKR
Overvalued by 58.6% based on the discounted cash flow analysis.
Market cap | $10.82 Billion |
---|---|
Enterprise Value | $11.61 Billion |
Dividend Yield | $0.1996 (0.25%) |
Earnings per Share | $2.9 |
Beta | 1.03 |
Outstanding Shares | 137,671,143 |
Avg 30 Day Volume | 599,907 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 25.32 |
---|---|
PEG | 22.81 |
Price to Sales | 3.84 |
Price to Book Ratio | 8.06 |
Enterprise Value to Revenue | 3.92 |
Enterprise Value to EBIT | 23.9 |
Enterprise Value to Net Income | 27 |
Total Debt to Enterprise | 0.11 |
Debt to Equity | 0.93 |
No data
No data
Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scienti c instruments and high-value analytical and diagnostic solutions enable...